Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangement, Collaborative Arrangements and Research and Development Arrangement - Pro Forma Information (Details) - Seagen [Member] - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Revenues subsequent to acquisition	$ 120
Net loss attributable to Pfizer Inc. common shareholders	$ (746)
Revenues		$ 60,632	$ 102,127
Net income/(loss) attributable to Pfizer Inc. common shareholders		$ (1,474)	$ 27,938
Diluted earnings/(loss) per share attributable to Pfizer Inc. common shareholders		$ (0.26)	$ 4.87